ALK and non-small cell lung carcinoma: The results from this study are consistent with findings from other studies, which showed that administering two or more ALK TKIs to patients with advanced ALK-positive NSCLC results in an mOS of up to 59 months, whereas administration of one ALK TKI is associated with a lower mOS ranging from 16 to 41 months [40,41,42,43,44,45,46,66,67,68,69].